Medical School · Year 2 · Psychiatry · includes a quiz and discussion video

Lecture 10: Psychiatric Emergencies and Psychopharmacology

Unit 2.6: Psychiatry

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the approach to acute suicidality and risk assessment
2. Explain the management of acute agitation and violence
3. Describe neuroleptic malignant syndrome and serotonin syndrome
4. Explain the principles of psychiatric hospitalization and commitment
5. Describe key psychopharmacology principles and drug interactions
6. Explain the approach to medication side effects and toxicity

Lecture Outline

I. Suicide Risk Assessment

Suicide represents a major public health concern, with approximately forty-five thousand deaths annually in the United States, making it the tenth leading cause of death. For every completed suicide, approximately twenty-five attempts occur. The demographics of suicide completion differ from those of attempts: men complete suicide approximately 3.5 times more often than women, while women attempt suicide more often than men. This difference reflects the lethality of methods used, with firearms being the most lethal method and more commonly used by men, while poisoning is more common among women.

Risk factors for suicide span multiple domains. Demographic factors include male sex, older adult age, white race, and being single, divorced, or widowed. Psychiatric factors include depression, bipolar disorder, schizophrenia, substance use disorders, and personality disorders, particularly borderline personality disorder. Prior behavior is the strongest predictor, with previous suicide attempt significantly elevating risk for future attempt and completion. Access to lethal means, particularly firearms, substantially increases risk. Acute factors include recent loss, hopelessness, agitation, and insomnia. Protective factors that decrease risk include social support, children in the home, religious beliefs, and engagement in treatment.

The assessment framework for suicidality evaluates several dimensions. Suicidal ideation ranges from passive wishes to die to active thoughts of killing oneself. Plan specificity determines whether the individual has identified a specific method and whether that method is available. Intent refers to the actual desire to die as opposed to ambivalence. Preparatory behaviors such as giving away possessions, writing notes, or researching methods indicate escalating risk. Protective factors including reasons for living should be actively explored.

Risk stratification guides disposition and treatment intensity. Low risk is characterized by ideation without plan and presence of strong protective factors. Moderate risk involves a plan without clear intent and presence of some risk factors. High risk is characterized by a plan with intent, access to means, and few protective factors. Imminent risk describes immediate plan with intent, available means, and inability to contract for safety, requiring immediate intervention.

<image>Panel A presents suicide epidemiology: 45,000 deaths/year in US, 25 attempts per death, men complete 3.5x more than women, women attempt more, firearms most lethal method. Panel B displays risk factors organized by category: demographic (male, older, white, unmarried), psychiatric (depression, bipolar, schizophrenia, SUD, personality disorders), behavioral (prior attempts strongest predictor), access (means availability especially firearms), acute (loss, hopelessness, agitation, insomnia), and protective (support, children, religious beliefs, treatment). Panel C illustrates the assessment framework: ideation (passive to active), plan (method and availability), intent (desire to die), preparatory behaviors (possessions, notes, research), protective factors (reasons for living). Panel D shows risk stratification levels: low (ideation, no plan, strong protective), moderate (plan without intent, some risk factors), high (plan with intent, access, few protective), imminent (immediate plan, intent, means, cannot contract safety).</image>

II. Suicide Intervention

Acute management of the suicidal patient prioritizes safety above all else. Means restriction involves removing access to lethal methods, with particular emphasis on firearms and stockpiled medications. One-to-one observation provides continuous monitoring by trained staff. Environmental safety requires removing objects that could be used for self-harm including sharps, ligature points, and glass. Medical evaluation should rule out delirium, intoxication, or medical conditions that may be contributing to suicidality.

Safety planning is a collaborative intervention that creates a personalized plan for managing suicidal crises. The safety plan includes identifying personal warning signs that indicate a crisis is developing, internal coping strategies that the individual can use independently, people and social settings that provide distraction, professional contacts and crisis resources including crisis lines, strategies for making the environment safe through means restriction, and identification of personal reasons for living. Safety planning differs from and has largely replaced no-suicide contracts, which lack evidence of effectiveness.

Disposition decisions follow from risk stratification. Hospitalization is indicated for patients at high or imminent risk who are unable to safety plan effectively. Partial hospitalization provides structured daytime programming with return home at night for moderate-risk patients with available supports. Intensive outpatient programs offer multiple weekly sessions for lower-risk patients who remain engaged. Outpatient follow-up is appropriate for low-risk patients with strong protective factors. Regardless of disposition, close follow-up is essential, as the period immediately following discharge from psychiatric hospitalization is one of particularly elevated risk.

Documentation of suicide risk assessment serves clinical and medicolegal purposes. All risk factors considered should be explicitly documented, including both those present and those absent. The clinical reasoning behind disposition decisions should be clearly articulated. If a safety plan was created, its components should be documented. Follow-up plans and communication with outpatient providers should be recorded.

<image>Panel A displays acute management priorities: means restriction (firearms, medications—shown with removal icons), one-to-one observation (continuous monitoring), environmental safety (remove sharps, ligature points, glass), medical evaluation (rule out delirium, intoxication, medical causes). Panel B presents safety plan components in sequential order: warning signs (personal crisis indicators), coping strategies (internal approaches), social contacts (people for distraction), professional contacts (crisis lines, providers), environment safety (means restriction at home), reasons for living (personal motivations). Panel C shows disposition decision tree: risk level determining hospitalization (high/imminent), partial hospitalization (moderate with supports), intensive outpatient (engaged, lower risk), outpatient with close follow-up (low, strong protective), with note about elevated risk post-discharge. Panel D illustrates documentation elements: risk factors (present and absent), clinical reasoning for disposition, safety plan components, and follow-up arrangements.</image>

III. Acute Agitation and Violence

Agitation in psychiatric settings can arise from multiple causes requiring identification for appropriate management. Psychiatric causes include psychosis with paranoia or disorganization, mania with grandiosity and irritability, and personality disorders with emotional dysregulation. Substance-related causes include intoxication with stimulants, alcohol, or phencyclidine, as well as withdrawal from alcohol, benzodiazepines, or opioids. Medical causes include delirium from infection, metabolic disturbance, or hypoxia, as well as hypoglycemia and undertreated pain. Environmental factors such as noise, crowding, restraints, and perceived threats can precipitate or exacerbate agitation.

De-escalation techniques should be attempted before pharmacological or physical interventions when safety permits. Verbal interventions use a calm, non-threatening voice and validate the patient's concerns while setting clear limits. Spatial management maintains safe distance, ensures access to exits, and reduces stimulation. Offering choices provides a sense of control, such as offering food, drink, or phone access. Limit-setting establishes clear, consistent expectations. Show of force, in which multiple staff members calmly demonstrate presence, represents a final step before medication and may prompt cooperation without physical intervention.

Pharmacological management varies based on the clinical situation. For undifferentiated agitation, the combination of haloperidol 5 mg, lorazepam 2 mg, and diphenhydramine 50 mg intramuscularly provides rapid sedation while covering multiple potential etiologies. For agitation in the context of known psychosis, atypical antipsychotics such as olanzapine 10 mg IM or ziprasidone 10-20 mg IM are effective. For alcohol withdrawal, lorazepam is preferred while antipsychotics should be avoided as they lower seizure threshold. When the patient will accept oral medication, this is preferable to intramuscular administration given faster onset and patient cooperation.

Physical restraints represent a last resort when de-escalation and medication are insufficient to maintain safety. Restraint use requires a physician order and documented indication. Time limits apply, with frequent reassessment required. Continuous monitoring of the restrained patient is mandatory, including circulation checks. De-escalation and removal of restraints should occur as soon as safely possible.

<image>Panel A presents causes of agitation by category: psychiatric (psychosis, mania, personality disorders), substance (stimulant intoxication, alcohol/benzo/opioid withdrawal), medical (delirium, hypoglycemia, pain), environmental (noise, crowding, restraints, perceived threats). Panel B displays de-escalation techniques in escalating order: verbal (calm voice, validate, set limits), spatial (safe distance, exit access, reduce stimulation), offer choices (food, drink, phone for sense of control), limit-setting (clear expectations), show of force (calm staff presence as final step before medication). Panel C shows pharmacological options: undifferentiated (haloperidol 5mg + lorazepam 2mg + diphenhydramine 50mg IM), psychosis (olanzapine 10mg IM or ziprasidone 10-20mg IM), alcohol withdrawal (lorazepam, avoid antipsychotics), oral preferred when accepted. Panel D illustrates restraint principles: last resort after de-escalation and medication, physician order required, time limits with frequent reassessment, continuous monitoring with circulation checks, de-escalate and remove ASAP.</image>

IV. Neuroleptic Malignant Syndrome

Neuroleptic malignant syndrome is a life-threatening reaction to dopamine-blocking medications characterized by a clinical tetrad of hyperthermia, muscular rigidity, altered mental status, and autonomic instability. Hyperthermia is often severe, with temperatures exceeding 40°C (104°F). Rigidity is generalized and described as lead-pipe rigidity, distinct from the cogwheeling of parkinsonism. Altered mental status ranges from confusion to coma. Autonomic instability manifests as tachycardia, labile blood pressure, and diaphoresis.

The causes of NMS include any dopamine-blocking agent. Antipsychotics carry the highest risk, with higher-potency typical antipsychotics such as haloperidol conferring greater risk than atypicals, though all can cause NMS. Withdrawal of dopaminergic medications, such as stopping levodopa in Parkinson's disease, can precipitate NMS. Antiemetics with dopamine-blocking properties, including metoclopramide and prochlorperazine, are often overlooked as potential causes. Risk factors include dehydration, exhaustion, rapid dose titration, and high ambient temperature.

Laboratory findings in NMS reflect widespread muscle injury and metabolic derangement. Creatine kinase is markedly elevated, often exceeding 1000 U/L and sometimes reaching tens of thousands, reflecting rhabdomyolysis. Leukocytosis is common. Metabolic acidosis results from muscle breakdown. Myoglobinuria can occur with severe rhabdomyolysis, risking acute kidney injury. Electrolyte abnormalities are common.

Treatment of NMS requires immediate intervention. The offending agent must be stopped immediately. Supportive care including ICU admission, aggressive cooling, and hydration forms the foundation of treatment. Dantrolene, a muscle relaxant that blocks calcium release from the sarcoplasmic reticulum, reduces rigidity and hyperthermia. Bromocriptine, a dopamine agonist, addresses the underlying dopamine blockade. Benzodiazepines may be used as adjuncts for rigidity and agitation. Untreated mortality approaches 10-20%, but outcomes are much better with early recognition and appropriate treatment.

<image>Panel A presents the clinical tetrad of NMS: hyperthermia (often greater than 40°C/104°F), rigidity (generalized, lead-pipe quality), altered mental status (confusion to coma), autonomic instability (tachycardia, labile BP, diaphoresis). Panel B displays causes and risk factors: antipsychotics (especially high-potency typicals, but all can cause), dopaminergic withdrawal (stopping levodopa), antiemetics (metoclopramide, prochlorperazine), with risk factors of dehydration, exhaustion, rapid titration, and heat. Panel C shows laboratory findings: CK markedly elevated (often greater than 1000, rhabdomyolysis), leukocytosis, metabolic acidosis, myoglobinuria (AKI risk), electrolyte abnormalities. Panel D illustrates treatment: stop offending agent immediately, supportive care (ICU, cooling, hydration), dantrolene (muscle relaxant), bromocriptine (dopamine agonist), benzodiazepines (adjunct), with 10-20% mortality if untreated.</image>

V. Serotonin Syndrome

Serotonin syndrome results from excess serotonergic activity and manifests with a clinical triad of neuromuscular, autonomic, and mental status changes. The Hunter Criteria provide validated diagnostic criteria requiring exposure to a serotonergic agent plus at least one of spontaneous clonus, inducible clonus with agitation or diaphoresis, ocular clonus with agitation or diaphoresis, tremor with hyperreflexia, or hypertonia with fever and clonus. Clonus, particularly spontaneous or easily inducible, is the most distinctive finding.

The clinical triad organizes the symptom presentation. Neuromuscular findings include clonus, hyperreflexia, tremor, and rigidity. Clonus is particularly characteristic and may be spontaneous, inducible with ankle dorsiflexion, or ocular. Autonomic findings include hyperthermia, diaphoresis, tachycardia, and diarrhea. Mental status changes include agitation and confusion.

Common causes involve combinations of serotonergic medications. The combination of SSRIs with MAOIs carries the highest risk and is contraindicated. SSRIs combined with tramadol is a common precipitating combination. SSRIs with triptans for migraine carry moderate risk. Any combination of multiple serotonergic agents creates additive risk. Single-agent serotonin syndrome can occur with overdose.

Treatment focuses on removing the precipitating agents and providing supportive care. All serotonergic medications should be discontinued immediately. Supportive care includes cooling, hydration, and monitoring in a setting appropriate to severity. Benzodiazepines help manage agitation and muscle rigidity. Cyproheptadine, a serotonin antagonist, is used in moderate to severe cases. Unlike NMS, serotonin syndrome typically resolves within 24-72 hours once the offending agents are removed, reflecting the shorter time course of pharmacodynamic effects.

<image>Panel A presents the Hunter Criteria: serotonergic agent exposure plus at least one of: spontaneous clonus, inducible clonus + agitation/diaphoresis, ocular clonus + agitation/diaphoresis, tremor + hyperreflexia, or hypertonia + fever + clonus, with clonus emphasized as the most distinctive finding. Panel B displays the clinical triad: neuromuscular (clonus—spontaneous, inducible, ocular; hyperreflexia; tremor; rigidity), autonomic (hyperthermia, diaphoresis, tachycardia, diarrhea), mental status (agitation, confusion). Panel C shows common drug combinations causing serotonin syndrome: SSRI + MAOI (highest risk, contraindicated), SSRI + tramadol (common), SSRI + triptans (moderate), multiple serotonergics (additive), single-agent overdose. Panel D illustrates treatment: stop serotonergics immediately, supportive care (cooling, hydration, monitoring), benzodiazepines (agitation, rigidity), cyproheptadine (serotonin antagonist for severe cases), with resolution typically in 24-72 hours.</image>

VI. Distinguishing NMS from Serotonin Syndrome

Key differences allow clinical differentiation of these two syndromes. Onset timing differs markedly, with NMS developing over days to weeks of antipsychotic exposure while serotonin syndrome typically develops within hours of medication change or overdose. Rigidity quality differs, with NMS producing lead-pipe rigidity and normal or decreased reflexes, while serotonin syndrome produces clonus and hyperreflexia. Pupils are typically normal in NMS but dilated in serotonin syndrome. Resolution time differs, with NMS requiring days to weeks for improvement while serotonin syndrome typically resolves within 24-72 hours once offending agents are stopped. Causative agents differ, with NMS caused by dopamine blockade and serotonin syndrome by serotonin excess.

Shared features can make differentiation challenging. Both syndromes produce hyperthermia, though temperature may be higher in NMS. Both cause altered mental status. Both produce autonomic instability including tachycardia and blood pressure changes. Both can be fatal if untreated. The clinical history regarding timing and medication exposure is often the most helpful distinguishing factor.

Other conditions must be considered in the differential diagnosis. Malignant hyperthermia occurs during anesthesia with exposure to volatile anesthetics or succinylcholine in genetically susceptible individuals. Anticholinergic toxicity produces hyperthermia with dry, flushed skin and normal reflexes along with characteristic anticholinergic symptoms. Sympathomimetic toxicity from stimulant use produces hyperthermia with agitation, tachycardia, and diaphoresis. Infection and sepsis should always be considered in febrile patients with altered mental status.

Prevention strategies address both syndromes. Drug interaction checking before prescribing serotonergic medications is essential. Appropriate washout periods when switching between MAOIs and other serotonergics, typically two weeks for most SSRIs and five weeks for fluoxetine, prevent serotonin syndrome. Patient education about warning signs allows early identification. Avoiding high-risk combinations when possible is the best prevention.

<image>Panel A presents a comparison table of NMS versus serotonin syndrome across key features: onset (days-weeks vs hours), rigidity (lead-pipe vs clonus/hyperreflexia), reflexes (normal or decreased vs increased), pupils (normal vs dilated), resolution (days-weeks vs 24-72 hours), cause (dopamine blockade vs serotonin excess). Panel B displays shared features that make differentiation challenging: hyperthermia (both, may be higher in NMS), altered mental status (both), autonomic instability (both), can be fatal (both), with medication history as most helpful distinguishing factor. Panel C shows differential diagnosis: malignant hyperthermia (anesthesia exposure), anticholinergic toxicity (dry, flushed, normal reflexes), sympathomimetic toxicity (stimulant use), infection and sepsis (always consider). Panel D presents prevention strategies: drug interaction checking, appropriate washout periods (2 weeks for most SSRIs, 5 weeks for fluoxetine when switching to/from MAOIs), patient education about warning signs, avoid high-risk combinations.</image>

VII. Psychiatric Hospitalization

Voluntary admission occurs when a patient with capacity agrees to psychiatric hospitalization for treatment. The patient consents to admission and treatment and generally retains the right to request discharge, though the hospital may initiate involuntary commitment proceedings if the patient meets criteria. Voluntary admission is preferred when possible as it promotes treatment alliance and patient autonomy.

Involuntary commitment allows hospitalization without patient consent when specific criteria are met. A mental illness must be present as the basis for commitment. Danger to self criterion is met when the individual is suicidal, actively self-harming, or unable to care for basic needs due to mental illness. Danger to others is met when the individual poses risk of violence to others due to mental illness. Grave disability, used in some jurisdictions, describes inability to meet basic needs for food, shelter, or medical care. The least restrictive alternative must be considered, meaning outpatient treatment options should be explored when appropriate.

The legal process for involuntary commitment involves multiple steps and varies by jurisdiction. Emergency hold, also called emergency detention, is physician-initiated and allows brief detention, typically 24-72 hours, for evaluation. Certification or petition for extended commitment involves a second evaluation and extends the hold, typically for 7-14 days. Judicial hearing provides court review with the patient represented by an attorney, protecting due process rights. Duration limits apply, with periodic review required for continued hospitalization.

Patient rights must be respected even during involuntary hospitalization. Patients have the right to legal representation and judicial hearing. Treatment refusal is generally permitted except when imminent danger requires emergency medication. Communication rights include access to phone, visitors, and mail, with limited exceptions. Patients have the right to information about the reason for commitment and the commitment process. Documentation of commitment criteria and the legal process must be thorough.

<image>Panel A displays voluntary admission features: patient with capacity consents to admission and treatment, right to request discharge (though conversion to involuntary may occur if criteria met), preferred approach promoting alliance and autonomy. Panel B presents involuntary commitment criteria: mental illness present, plus danger to self (suicidal, self-harm, unable to care for self), or danger to others (violence risk), or grave disability (cannot meet basic needs), with least restrictive alternative considered. Panel C illustrates the legal process as sequential steps: emergency hold (physician-initiated, 24-72 hours), certification (second evaluation, extends 7-14 days), judicial hearing (court review, attorney representation, due process), periodic review for continued hospitalization. Panel D shows patient rights: legal representation and hearing, treatment refusal (except emergency), communication (phone, visitors, mail), information about commitment reason, with thorough documentation required.</image>

VIII. Psychopharmacology Principles

Pharmacokinetic principles govern drug absorption, distribution, metabolism, and elimination. Absorption varies with formulation and food effects, with some medications requiring food for optimal absorption. Distribution depends on protein binding and volume of distribution, affecting both steady-state levels and duration of effect. Metabolism occurs primarily through cytochrome P450 enzymes in the liver, with genetic polymorphisms affecting metabolic capacity. Elimination half-life determines dosing frequency and time to steady state, which is reached after approximately five half-lives.

Key CYP450 interactions affect many psychiatric medications. CYP2D6 metabolizes many tricyclic antidepressants and antipsychotics and is inhibited by fluoxetine, paroxetine, and bupropion, potentially increasing levels of substrate drugs. CYP3A4 metabolizes many benzodiazepines and buspirone and is inhibited by fluvoxamine and nefazodone. CYP1A2 metabolizes clozapine and olanzapine, is inhibited by fluvoxamine, and is induced by smoking, meaning smokers require higher doses and levels may rise dangerously when smoking cessation occurs.

Pharmacodynamic principles describe drug-receptor interactions. Receptor binding affinity and selectivity determine both therapeutic effects and side effects. Therapeutic lag describes the delay between drug initiation and clinical response, often four to six weeks for antidepressants due to downstream neuroplastic changes. The dose-response relationship varies among drugs and individuals. Tolerance may develop to some effects with continued use.

Therapeutic drug monitoring is indicated for certain psychiatric medications. Lithium has a narrow therapeutic index requiring regular level monitoring to maintain efficacy while avoiding toxicity. Valproate monitoring helps optimize dosing within the therapeutic range. Carbamazepine monitoring is complicated by autoinduction, in which the drug induces its own metabolism, requiring dose adjustment over time. Clozapine level monitoring may optimize dosing. Tricyclic antidepressant monitoring addresses toxicity concerns given the narrow margin between therapeutic and toxic levels.

<image>Panel A presents pharmacokinetic principles: absorption (formulation, food effects), distribution (protein binding, volume of distribution), metabolism (CYP450 enzymes, genetic polymorphisms), elimination (half-life determines dosing and time to steady state at 5 half-lives). Panel B displays key CYP450 interactions: 2D6 (substrates: TCAs, many antipsychotics; inhibitors: fluoxetine, paroxetine, bupropion), 3A4 (substrates: benzodiazepines, buspirone; inhibitors: fluvoxamine, nefazodone), 1A2 (substrates: clozapine, olanzapine; inhibitor: fluvoxamine; inducer: smoking). Panel C shows pharmacodynamic principles: receptor binding (affinity, selectivity), therapeutic lag (4-6 weeks for antidepressants, neuroplasticity), dose-response relationship, tolerance development. Panel D presents therapeutic drug monitoring: lithium (narrow therapeutic index, regular monitoring), valproate (optimize dosing), carbamazepine (autoinduction complicates), clozapine (optimize dosing), TCAs (toxicity concern).</image>

IX. Medication Side Effects and Toxicity

Lithium toxicity manifests along a severity spectrum correlated with serum levels. Mild toxicity at levels of 1.5-2.0 mEq/L presents with nausea, vomiting, diarrhea, and fine tremor. Moderate toxicity at 2.0-2.5 mEq/L adds confusion, ataxia, and dysarthria. Severe toxicity above 2.5 mEq/L produces seizures, coma, and cardiac arrhythmias. Treatment involves holding lithium, aggressive intravenous hydration, and hemodialysis for severe toxicity. Prevention requires patient education about maintaining hydration, avoiding NSAIDs and other interacting medications, and monitoring during illness.

SSRI discontinuation syndrome occurs when SSRIs are stopped abruptly, particularly those with shorter half-lives. Symptoms include dizziness, nausea, electric shock sensations described as brain zaps, irritability, and insomnia. Onset typically occurs within days of stopping or reducing the medication. Duration is usually one to two weeks. Risk is highest with shorter half-life agents such as paroxetine and lowest with long half-life fluoxetine. Prevention involves gradual tapering rather than abrupt discontinuation.

Antipsychotic side effects require monitoring and management. Extrapyramidal symptoms and acute dystonia, occurring within hours to days, respond to anticholinergic medications such as benztropine or diphenhydramine. Akathisia, a subjective sense of restlessness occurring within days to weeks, may respond to beta-blockers or benzodiazepines. Tardive dyskinesia, involuntary movements developing over months to years of treatment, may be irreversible but can be treated with VMAT2 inhibitors such as valbenazine or deutetrabenazine. Metabolic effects including weight gain, diabetes, and dyslipidemia require ongoing monitoring. QTc prolongation with arrhythmia risk requires ECG monitoring with certain agents.

Overdose presentations vary by medication class. Tricyclic antidepressant overdose is particularly dangerous, causing cardiac toxicity with widened QRS and arrhythmias, seizures, and anticholinergic effects. Treatment includes sodium bicarbonate for cardiac toxicity. Lithium overdose causes neurological and cardiac toxicity as described above. SSRI overdose is generally safer but can cause serotonin syndrome. Bupropion overdose carries significant seizure risk. Valproate overdose causes hepatotoxicity and encephalopathy.

<image>Panel A presents lithium toxicity severity spectrum: mild 1.5-2.0 mEq/L (nausea, vomiting, diarrhea, tremor), moderate 2.0-2.5 (confusion, ataxia, dysarthria), severe greater than 2.5 (seizures, coma, arrhythmias), with treatment (hold lithium, IV hydration, dialysis for severe) and prevention (hydration, avoid NSAIDs, monitor during illness). Panel B shows SSRI discontinuation: symptoms (dizziness, nausea, brain zaps, irritability, insomnia), onset within days, duration 1-2 weeks, highest risk with paroxetine (short half-life), lowest with fluoxetine (long half-life), prevention through gradual taper. Panel C displays antipsychotic side effects by timing: acute dystonia (hours-days, anticholinergics), akathisia (days-weeks, beta-blockers), tardive dyskinesia (months-years, VMAT2 inhibitors), metabolic (ongoing monitoring), QTc prolongation (ECG monitoring). Panel D presents overdose by class: TCAs (cardiac toxicity, seizures, treat with sodium bicarbonate), lithium (neuro and cardiac, dialysis), SSRIs (relatively safe, serotonin syndrome possible), bupropion (seizures), valproate (hepatotoxicity, encephalopathy).</image>

X. Special Emergency Situations

Acute dystonia is a dramatic presentation requiring prompt recognition and treatment. Clinical presentation includes sustained muscle contractions causing torticollis, oculogyric crisis with eyes deviated upward, trismus, and laryngospasm which can be life-threatening. Cause is dopamine blockade from antipsychotics or antiemetics, typically occurring within hours to days of starting or increasing medication. Treatment with benztropine 1-2 mg IM or diphenhydramine 50 mg IM produces rapid response, often within minutes.

Catatonia is a psychomotor syndrome that can occur in multiple contexts and requires specific recognition and treatment. Signs include stupor with decreased responsiveness, mutism, catalepsy with maintenance of posturing, waxy flexibility allowing limbs to be positioned by examiner, negativism with resistance to instructions, posturing, mannerisms, stereotypies, and echolalia or echopraxia. Causes include mood disorders, psychotic disorders, medical conditions, and it may occur as a distinct syndrome. Critically, treatment differs from typical psychosis: benzodiazepines such as lorazepam are first-line, and antipsychotics may actually worsen catatonia. Electroconvulsive therapy is highly effective for refractory cases.

Excited delirium, though controversial as a diagnosis, describes a clinical presentation requiring emergent intervention. Presentation includes extreme agitation, hyperthermia, and apparent superhuman strength, typically in the context of stimulant intoxication or excited psychiatric states. The risk of sudden death from cardiac arrhythmia is the primary concern. Management involves rapid sedation, aggressive cooling, and continuous cardiac monitoring.

Medication-induced movement disorders follow a characteristic timeline that aids recognition. Acute dystonia occurs within hours to days. Akathisia develops over days to weeks. Parkinsonism emerges over weeks to months. Tardive dyskinesia develops over months to years of chronic antipsychotic exposure and may be irreversible. Understanding this timeline helps identify the cause of new movement abnormalities in patients on antipsychotics.

<image>Panel A presents acute dystonia: presentation (torticollis, oculogyric crisis, trismus, laryngospasm—potentially life-threatening), cause (dopamine blockade from antipsychotics or antiemetics), treatment (benztropine 1-2mg IM or diphenhydramine 50mg IM, rapid response within minutes). Panel B shows catatonia: signs (stupor, mutism, catalepsy, waxy flexibility, negativism, posturing, echolalia/echopraxia), causes (mood, psychotic, medical disorders), treatment (benzodiazepines first-line—importantly different from treating psychosis, antipsychotics may worsen, ECT for refractory). Panel C displays excited delirium: presentation (extreme agitation, hyperthermia, superhuman strength), context (stimulants, excited states), risk (sudden cardiac death), management (rapid sedation, cooling, cardiac monitoring). Panel D illustrates movement disorder timeline: acute dystonia (hours-days), akathisia (days-weeks), parkinsonism (weeks-months), tardive dyskinesia (months-years, may be irreversible).</image>

Summary

• Suicide risk assessment evaluates ideation, plan, intent, preparatory behaviors, and protective factors to stratify risk and guide disposition
• Safety planning is a collaborative intervention including warning signs, coping strategies, contacts, means restriction, and reasons for living
• Agitation management follows a hierarchy from de-escalation to pharmacotherapy to restraints as a last resort
• Neuroleptic malignant syndrome presents with hyperthermia, lead-pipe rigidity, altered mental status, and autonomic instability; treatment includes stopping antipsychotic, dantrolene, and bromocriptine
• Serotonin syndrome presents with clonus, hyperreflexia, autonomic instability, and altered mental status; treatment includes stopping serotonergics and cyproheptadine for severe cases
• Key differences: NMS develops over days-weeks with lead-pipe rigidity; serotonin syndrome develops within hours with clonus and hyperreflexia
• Involuntary commitment requires mental illness plus danger to self, danger to others, or grave disability
• Lithium toxicity correlates with serum levels and requires holding lithium, hydration, and dialysis for severe cases
• Acute dystonia from dopamine blockade responds rapidly to anticholinergics; catatonia is treated with benzodiazepines first-line
• Movement disorder timeline: acute dystonia (hours-days), akathisia (days-weeks), parkinsonism (weeks-months), tardive dyskinesia (months-years)

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown